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Abstract
Background: In an ongoing clinical trial, the genetic and environmental risk assessment (GERA) blood test offers
subjects information about personal colorectal cancer risk through measurement of two novel low-to-moderate risk
factors. We sought to examine predictors of uptake of the GERA blood test among participants randomized to the
Intervention arm.
Methods: Primary care patients aged 50 to 74 years eligible for colorectal cancer screening are randomized to
receive a mailed stool blood test kit to complete at home (Control) or to the control condition plus an in-office
blood test called GERA that includes assessment of red blood cell folate and DNA-testing for two MTHFR
(methylenetetrahydrofolate reductase) single nucleotide polymorphisms (SNPs) (Intervention). For the present study,
baseline survey data are examined in participants randomized to the Intervention.
Results: The first 351 intervention participants (161 African American/190 white) were identified. Overall, 249
(70.9%) completed GERA testing. Predictors of GERA uptake included race (African American race, odds ratio (OR)
0.51 (0.29 to 0.87)), and being more knowledgeable about GERA and colorectal cancer screening (OR 1.09 (1.01 to
1.18)). Being married (OR 1.81 (1.09 to 3.00)) was also significant in the multivariable model.
Conclusions: Participant uptake of GERA testing was high. GERA uptake varied, however, according to socio-
demographic background and knowledge.
Background
Colorectal cancer (CRC) is the third most common cancer
of US men and women, with approximately 150,000 new
diagnoses in 2012 [1]. While a small number of CRCs are
known to be caused by mutations in high penetrance can-
cer genes such as those associated with familial adenoma-
tous polyposis or Lynch syndrome, most cases of CRC
appear to be sporadic, and likely arise from risks associated
with both low penetrance genes and environmental risks
such as dietary or toxin exposures. Colonoscopy screening
in adults is proven to lower the risk of developing CRC
and is endorsed by the US Preventive Services Task Force
[2]. Despite recent increases in general US population
screening, improvements are still needed. Screening rates
among underserved populations continue to lag behind
those of white Americans [3]. Improving CRC screening
rates remains a national health care goal [2,3].
Experts have hypothesized that providing personalized
genetic susceptibility feedback may serve as an important
link between public health goals and individual motivation
to engage in healthy behaviors such as cancer screening
[4,5]. A number of SNPs associated with generally modest
(5 to 20%) increases in cancer risk have been identified,
and several studies have to date examined the impact of
genetic susceptibility feedback on health behaviors either
through hypothetical scenarios or through offering single-
gene or so-called multiplex genetic testing [6-9]. In adult
populations both at increased risk for cancer and unse-
lected for cancer risk, interest in genetic susceptibility
feedback is generally high, and experts have supported a
potential for large impact on prevention behaviors [4,5]. A
recent meta-analysis of the impact of genetic susceptibility
feedback on smoking and physical activity outcomes, how-
ever, suggested limited effectiveness [10].
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Clinical risk assessment for increased genetic risk of
disease in adults currently consists primarily of intensive
counseling and testing for mutations in highly penetrant
risk genes. Interest in and uptake of novel forms of genetic
susceptibility feedback testing, examined largely through
research, remains variable, and has been shown to be mod-
erated by a number of demographic, psychological, and
psychosocial factors [6-8,11,12]. Little is currently known
about how patients will react to a genetic susceptibility
feedback test that examines a combination of genetic and
environmental (for example, dietary) risk factors, and
whether such a combination test might prove to be a
superior stimulus for health behavior change compared to
a genetic susceptibility feedback test alone. Research has
demonstrated that the public assigns similar importance to
genetic and behavioral sources of risk across a wide range
of adult diseases, supporting at face value the appeal of
gene-environment susceptibility testing [6,13,14]. Further,
studies have suggested that African Americans (AAs; ver-
sus white) may have more positive attitudes towards
genetic testing research in which a dual genetic/behavioral
risk model of disease is emphasized [13,14].
The majority of studies that examine interest in and uti-
lization of genetic testing have been performed among
individuals with a strong personal or family history of
disease who are eligible for predictive genetic testing (for
example, BRCA1/2). Here, testing uptake has been asso-
ciated with elevated perceived cancer risk, higher knowl-
edge/awareness of genetic testing for cancer risk, and
demographic factors including white race. Recent litera-
ture examining SNP-based genetic susceptibility feedback
testing provides additional insight into reasons why indivi-
duals may or may not pursue genetic testing presented in
a different context. For example, like patients seeking a
predictive genetic testing for cancer risk (for example,
BRCA1/2), individuals with elevated objective or perceived
risk of adult disease may seek genetic susceptibility feed-
back due to increased perceived relevance of the testing to
their health [6,7,9,12,15], increased cancer worry [6,8], or
to support an already elevated perceived risk of developing
cancer or motivation to change behavior, even when test-
ing for a low penetrance risk gene [6,8,16]. These same
high-risk individuals may also express strong intentions to
modify behaviors dependent on further information about
risk [7,8,11,15], but may ultimately fail to move forward
with testing due to practical (for example, access) and psy-
chological barriers (for example, low motivation or aware-
ness) [11]. On the contrary, motivations for uptake of
genetic susceptibility feedback testing in average risk
groups may derive from other sources. Perceived relevance
of genetic susceptibility testing for disease risk is likely to
be lower in this group. Taking this into consideration,
motivations for testing may be driven by psychological
optimism toward genetic testing and genetics research,
favorable views of knowledge enhancement afforded by
testing, or to positively support currently unattained per-
sonal health goals [9]. In other instances, these individuals
might also use a genetic susceptibility feedback result to
defend a current adverse health behavior (for example,
smoking, screening avoidance), or may be more apt to
avoid testing due to distrust of test results or a desire to
avoid negative information about a current adverse health
behavior [9,14].
Moreover, among average risk groups, low objective
knowledge of CRC risks, screening, or standard tests
coupled with less experience with genetics and genetic
testing may be central to attitudes and behaviors toward
genetic susceptibility feedback testing. Multiple studies
have shown that the general public lacks basic knowledge
and understanding about genetics and genetic testing
[17-20]. Comparatively lower knowledge and awareness of
genetic tests for cancer risk has also been recorded among
less educated individuals, and among minorities and
underserved individuals relative to white Americans
[17,18,21-25], particularly AAs [21,26-28]. Low knowledge
of genetic testing has been negatively associated with test-
ing interest and testing uptake in the literature examining
predictive genetic testing [17,18,22-24]. In particular, stu-
dies have reported low knowledge of genetics associated
with strong interest and/or intention to test but yet ulti-
mately low completion of testing, particularly in under-
served and less educated groups. Higher overall
information needs and information seeking support needs
in this group may contribute to the intention-uptake dis-
connect [6,14,29].
Our research group recently reported on the feasibility of
offering a gene-environment risk assessment (GERA) study
in which testing results for two markers of CRC risk,
serum folate level and two SNPs in the MTHFR gene
(methylentetrahydrofolate reductase), were made available
to adults at average risk for CRC [30,31]. An ongoing ran-
domized study is currently examining the impact of GERA
testing on CRC screening compliance. In routine study
monitoring, an unexplained lower rate of completion of
GERA testing in subjects randomized to the intervention
arm was detected. In the current study, we examined the
magnitude of non-uptake of GERA testing among partici-
pants randomized to the intervention arm, and tested sev-
eral hypotheses for why test uptake was not occurring. Our
hypotheses and analyses were guided by the existing litera-
ture and the Preventive Health Model and Precaution
Adoption Process Model behavioral models, which
together informed the selection of measures and outcomes
in the larger trial. Our first hypothesis was that lower
knowledge (of genetics, gene-environment risks, and CRC)
in the study population would be associated with lower
uptake of the GERA test. We anticipated that modest to
low levels of knowledge would be seen due to the novel
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experimental nature of GERA and the low objective risk of
CRC in this average risk adult population contributing to
low perceived relevance of the GERA test. Secondly, we
hypothesized that AA race would also be associated with
lower uptake of the GERA test. Despite the possible attrac-
tiveness of a combination gene-environment test to AAs
and expressed interest and consent to be in the study, we
believed that actual GERA testing uptake would be less
than in white participants, similar to the low uptake of the
testing among AAs who completed baseline surveys in
research from the Multiplex initiative research [6,29,32]
and Bloss et al. [33]. A third hypothesis was that perceived
risk of cancer among participants would not be associated
with GERA uptake, as we anticipated generally low levels
of perceived risk in this cohort. Finally, we further hypothe-
sized that race, with its previously documented associations
to knowledge of genetics and genetic risk perception,
would moderate the relationships of the other two predic-
tors of interest to uptake of the GERA test. In line with the
literature and our behavioral models, we included age, sex,
educational attainment, and marital status as relevant cov-




A detailed description of the GERA methods has been
published [31]. In brief, eligible participants for the
GERA study include average risk adults non-compliant
with recommended CRC screening. Participants are
drawn from family medicine and internal medicine prac-
tices affiliated with Jefferson Medical College. A software
program screens the billing and scheduling databases of
the participating medical practices for eligible patients.
Initially only patients with a scheduled appointment were
targeted for recruitment. Because of slow accrual, the
investigative team expanded recruitment to patients
without appointments. Potential participants are mailed a
personalized invitation to participate. Telephone contact
is made with eligible participants who do not opt out to
obtain informed consent and to administer a baseline
survey. All patients are given the opportunity to ask
questions before the informed consent document is
signed. Following completion of the survey, participants
are randomly assigned 1:2 to a usual care/Control group
or the Intervention group, usual care plus GERA (red
blood cell folate level plus assessment of two germ-line
SNPs in the methylenetetrahydrofolate reductase gene
(MTHFR)). An appointment for the GERA blood draw is
made, either in conjunction with or independent of a
physician office visit. A second informed consent to have
the blood draw and GERA risk testing is obtained at the
testing appointment.
At the time of the baseline survey, participants were
alerted that they could be invited to have a blood draw at
the time of the decision counseling. At decision counsel-
ing, participants were presented with the GERA pamphlet
and received education emphasizing how GERA informa-
tion might inform individual decision making about CRC
screening. The concept that GERA information is not a
substitute for CRC screening, but rather a method to stra-
tify risk, is emphasized. It was also emphasized that GERA
would not provide a numerical magnitude of risk eleva-
tion, but would only gauge CRC risk as ‘not elevated’ or
‘elevated’. Participants are allowed to take the GERA
pamphlet home. The pamphlet contains a toll-free tele-
phone number if the recipient has further questions.
Study population
A flow chart of the study participants is shown in Figure 1.
At the time of the current analysis, 580 participants had
enrolled in the trial and were randomized. The trial was
recently closed after 748 participants signed consent and
were randomized. Of the 580 participants analyzed here,
382 (65.9%) were randomized to the Intervention group.
Seventeen of these participants (17/382) reported a race
other than AA or white and were excluded from the cur-
rent analysis. Of the remaining AA and white participants
(n = 365), 2 individuals (0.5%) attended the testing visit
but refused to sign informed consent for the blood draw.
An additional 12 participants (3.3%) were excluded for
study ineligibility (n = 6), unsuccessful blood draw (n = 2),
or miscellaneous causes (n = 4). Thus, the sample size for
this analysis includes 351 participants, representing 91.9%
(351/382) individuals randomized to the Intervention who
were eligible for the GERA test. A secondary analysis of
patients accepting versus declining participation in the
GERA trial found that participants were younger than
non-participants (P < 0.001), but no differences by race or
gender were seen.
Participants have multiple opportunities to complete
the GERA risk testing, and several repeat attempts to
schedule testing are made. Reasons for GERA testing
non-completion include: 1) failure of the patient to
attend a scheduled appointment for consent and blood
draw; 2) inability of study staff to successfully schedule
an appointment for blood draw and consent after pre-
viously obtaining a patient’s consent to enroll in the
study. The vast majority of patients who did not com-
plete GERA testing either cancelled their testing visit on
multiple occasions or simply did not show up, and did
not respond to multiple attempts to reschedule.
Conceptual model and study measures
Selection of measures for the baseline survey for the lar-
ger randomized GERA clinical trial is guided by two
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behavioral health models, the Preventive Health Model
and the Precaution Adoption Process Model [31,36,37].
The former predicts that preventive health behaviors
may be influenced by demographic factors, cognitive
perceptions of the health threat, and perceived risk of
the health threat [36,37]. In the current study, with
influence from the existing literature of genetic suscept-
ibility testing and predictive genetic testing, and our
own research examining the association of knowledge to
decisions about genetic testing [16], we elected to focus
in particular on race as the primary demographic factor
of interest, objective knowledge (of gene-environment
risk of cancer, genetics, and colorectal cancer screening)
as the primary cognitive factor, and perceived risk (here,
comparative risk) as the predominant potential predic-
tors within the model, and considered uptake of the
GERA screening test as the target screening behavior.
Age, race, gender, marital status, education, and knowl-
edge are obtained from the baseline survey. This survey
contains 20 face-valid true/false items developed by the
investigative team assessing knowledge of colorectal can-
cer, genetics and gene-environmental risk for colorectal
cancer (Figure 2). Additional baseline survey items assess
perceived risk of CRC by a single item measured on a five-
point Likert scale (’compared to other persons my age, I
am at lower risk for colon cancer’), and items assessing
marital status, gender, education, and age. Self-reported
race was recorded via eight categories (American Indian
or Alaskan Native, Asian, Black or African American,
Native Hawaiian or other Pacific Islander, White, More
than one race, Don’t know, and Refused). Ethnicity was
recorded as Hispanic or Latino, Not Hispanic or Latino,
Don’t know, or Refused. For this analysis, individuals




Did not enroll (n=1743)
Not randomized (n=8)
Randomized to control arm (n=198)
Intervention arm (n=382)
Current study population (n=351)
Race other than White or African 
American (n=17)
Refused blood draw consent (n=2)
Found to be ineligible (n=6)
Unsuccessful blood draw or other (n=6)
Figure 1 Flowchart for study subjects drawn from the Gene Environment Risk Assessment (GERA) trial.
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groups represented 97% of study participants. A small
number of individuals reporting Black or White race and
Hispanic or Latino ethnicity are included in these analyses.
Analyses
Age is treated as a continuous variable. Knowledge
includes total knowledge items answered correctly (n = 20
items). Knowledge sub-scores are also reported for CRC
risk factor and screening items (knowledge of CRC, n =
10) and for dietary and genetic risk factor items (knowl-
edge of GERA, n = 10). GERA testing uptake is reported as
the proportion of participants randomized to the GERA
intervention that completed testing. Univariate associations
between predictors and uptake are reported as odds ratios
(OR) with 95% confidence intervals (CI). Multivariable
logistic regression was used to examine the association of
race, perceived risk, and knowledge to GERA testing
uptake. Moderation by race was assessed by creating an
interaction term and testing its significance in the multi-
variable model. All confidence intervals are reported at the
95% level, and alphas are reported as significant when
< 0.05. All analyses were performed using STATA9SE.
The GERA study has been approved by the Institu-
tional Review Boards of Fox Chase Cancer Center and
Jefferson Medical College, and conforms to the Declara-
tion of Helsinki.
Results
Characteristics of participants stratified by GERA uptake
Baseline characteristics of participants randomized to
the GERA testing arm and considered for this analysis
are presented in Table 1. The mean age among all parti-
cipants was 60.1 years. Participants were more likely to
be female (59.0%) and white (54.1%). Approximately
one-third had a college degree (36.8%). Despite the
study inclusion of low risk participants by personal and
family history criteria, 151 (43.0%) participants estimated
their risk of CRC to be higher than other persons their
age. On the 20-item CRC knowledge assessment, med-
ian number of items correct among all participants was
12/20 (standard deviation 3.67).
Uptake of GERA risk testing
Among the 351 subjects eligible for GERA risk testing,
249/351 (70.9%) completed testing. Some variability in
uptake by baseline demographic covariates was seen. Uni-
variate associations are presented in Table 1. Subjects who
completed GERA testing were more likely to be married
Figure 2 Knowledge items from the baseline questionnaire of the Gene Environment Risk Assessment (GERA) trial.
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(OR 1.78 (95% CI 1.11 to 2.84)) and to have a college
degree (OR 3.28 (95% CI 1.80 to 5.98)) compared to those
who did not complete testing. We also examined the
relationships of the primary predictors we were examining
to uptake of GERA risk testing by participants. Predictors
included race, perceived risk, and knowledge. AA partici-
pants were significantly less likely to complete GERA risk
testing compared to white participants (OR 0.36 (95% CI
0.22 to 0.58)). Total knowledge score was also associated
with testing completion (OR 1.14 (95% CI 1.07 to 1.21)).
There was no association seen between perceived risk for
colon cancer and uptake of testing.
Multivariable model
A multivariable logistic regression model including the
three predictors (race, perceived risk, and knowledge)
was next developed to further examine the relationships
identified in the univariate analyses (Table 2). Covariates
age, sex, marital status, and educational attainment were
included in the model. In the complete model contain-
ing race, knowledge, and perceived risk, AA race was
negatively associated with GERA testing completion
(OR 0.51 (95% CI 0.29 to 0.87)), while increasing knowl-
edge score was positively associated with completion
(OR 1.09 (95% CI 1.01 to 1.18)). Interestingly, being
married was also found to be significantly associated
with uptake of testing in the model (OR 1.81 (95% CI
1.09 to 3.00)). The role of race as a moderator of the
relationship between knowledge and uptake or perceived
risk and uptake was assessed using interaction terms,
but both terms were found to be non-significant.
Discussion
We found incomplete uptake/completion of an experi-
mental GERA test of modest predictive utility despite
extensive efforts to complete risk testing in patients ran-
domized to the intervention group in the GERA trial.
AA race and individuals with lower knowledge (of CRC,
screening, and gene-environment risks and testing) were
less likely to complete GERA risk testing in univariate
and multivariable logistic regression analyses, while per-
ceived cancer risk was not associated with uptake.
Knowledge and race were each significant predictors of
uptake of testing in the multivariable model. Race was
not found to moderate the association of knowledge to
uptake or perceived risk to uptake.
These findings support our first two hypotheses, that
knowledge and race are independent predictors of
Table 1 Characteristics of participants eligible to undergo GERA risk testing (n = 351)
GERA risk testing uptake
Yes No
Subject characteristics n = 249 (70.9) n = 102 (29.1) OR 95% CI
Age: mean (SD) 59.8 (7.2) 60.8 (8.1) 0.98 0.95-1.01
Sex: n (%)
Female 148 (71.5) 59 (28.5) 1.07 0.67-1.70
Male 101 (70.1) 43 (29.9) – –
Racea: n (%)
African American 96 (59.6) 65 (40.4) 0.36b 0.22-0.58
White 153 (80.5) 37 (19.5) – –
Marital status: n (%)
Married 131 (77.1) 39 (22.9) 1.78c 1.11-2.84
Unmarried/other 118 (65.2) 63 (34.8) – –
Education: n (%)
High school or less 69 (61.1) 44 (38.9) Referent Referent
Some college 72 (66.1) 37 (33.9) 1.24 0.72-2.15
College graduate or more 108 (83.7) 21 (16.3) 3.28b 1.80-5.98
Perceived riskd: n (%)
Agee (perceived average risk) 76 (75.3) 25 (24.7) Referent Referent
Unsure 71 (71.7) 28 (28.3) 0.83 0.44-1.56
Disagree (perceived elevated risk) 102 (67.6) 49 (32.5) 0.68 0.39-1.21
CRC knowledge mean score: median (SD)
All questions (20 items) 12 (3.53) 10 (3.73) 1.14b 1.07-1.21
Risk factors and screening (10 items) 7 (1.86) 6 (2.05) 1.33b 1.18-1.50
Diet and genetics (10 items) 5 (2.16) 5 (2.11) 1.14c 1.02-1.27
aIncludes nine individuals of Hispanic ethnicity (eight AA, one White). bP < 0.001. cP = 0.02. d’Compared with other persons my age, I am at lower risk for colon
cancer’. CI, confidence interval; CRC, colorectal cancer; GERA, Gene Environment Risk Assessment; OR, odds ratio; SD, standard deviation; SE, standard error.
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uptake of the GERA test, and are consistent with the
published literature. The importance of objective knowl-
edge of a moderate risk gene-environment susceptibility
test in moderating uptake in an average risk population
is notable because this association is adjusted for educa-
tion level and is identified in a consented clinical trial
population enriched in AAs. This suggests that average
risk patients may be more skeptical of an experimental
genetic test about which they have limited understand-
ing and exposure [9,12,15], or in the case of the GERA
population, reluctant to have a non-standard test that
may serve to remind them of their non-compliance with
CRC screening [9,14]. Lower knowledge may also have
contributed to participants questioning the relevance of
the test for them, given their minimal family history and
given possible perceptions of low personal risk of being
folate deficient [6,8,9]. The significance of our findings
associating race with low uptake of GERA are also inter-
esting. While a negative association between AA race
and uptake of predictive genetic testing has been docu-
mented several times in the literature, it has, to our
knowledge, not been observed in an objectively low-risk
population offered a dual gene environment susceptibil-
ity feedback assessment. Though research from White et
al. [13] has suggested that research that considers both
genetic and exposure-related causes of disease to be
more acceptable to AAs, AA participants may have been
less likely to complete GERA testing because of reasons
not measured in the current analysis. Socioeconomic
barriers, higher prevalence of fatalism toward colon can-
cer risk or distrust of the medical system and clinical
trial research [34], or a higher likelihood of having
already decided to get CRC screening, may all contri-
bute to reducing the perceived relevance of the GERA
test in the study population [8].
Our third hypothesis was also supported by the analyses,
but should be interpreted with more caution. We antici-
pated low perceived risk in the GERA cohort based on the
study selection criteria, and thus did not predict an asso-
ciation with GERA uptake in line with the Preventive
Health Model. We were therefore surprised to find that
43% of the total study population reported their CRC risk
to be higher than average. Nonetheless, perceived risk was
not significant in the final model, and no interaction
between perceived risk and race was identified. Elevated
perceived risk here may be related to study selection bias,
with more concerned individuals being more likely to con-
sent to the research, or to changing perceptions of risk
among participants within the context of the study. None-
theless, that perceived risk was not significant in the
model suggests that even those individuals who perceived
higher risk may not have seen the GERA test as valuable
to them, perhaps because they already recognized that
they were higher risk, or because the GERA test did not
quantify risk, but only reported risk qualitatively as ele-
vated or not elevated. Our final hypothesis, that race may
moderate both the relationships of knowledge and per-
ceived risk to uptake, was disproven in our analyses. This
both suggests that the mitigating effects of low knowledge
on uptake of the GERA test were independent of race, and
that race-specific variability in perceived risk was not influ-
ential in these findings.
The strength of the positive association of testing uptake
with being married was unexpected. Marital status has
previously been shown to predict prostate cancer screen-
ing [38], but most studies of CRC screening have not
shown an association [39]. Being married may be asso-
ciated with improved adherence to health behaviors such
as cancer screening [40], and may indirectly be associated
with follow-through for the GERA test by a consented
patient. In line with the Precaution Adoption Process
Model, spousal support may have served to motivate
conflicted participants to complete the GERA testing in
the setting of questionable health relevance or benefit to
the study test. The relative impact of marital status may
also be particularly enhanced by the genetic nature of the
GERA test. Spouses may be particularly motivated to
understand genetic risks in their partners and thus to
motivate completion of study participation because of the
assumed far-reaching implications of even a small
Table 2 Multivariable models examining predictors of
GERA risk testing uptake
All participants




Total knowledge 1.09 (1.01-1.18) 0.03
Race
White Referent Referent
African American 0.51 (0.29-0.87) 0.01
Perceived risk
Below average Referent Referent
Unsure 0.92 (0.45-1.85) 0.80
Above average 0.78 (0.42-1.44) 0.43
Education
High school or less Referent Referent
Some college 0.91 (0.50-1.65) 0.75
College graduate + 1.67 (0.83-3.36) 0.15
Marital status
Unmarried/other Referent Referent






Results adjusted for age and sex. CI, confidence interval; GERA, gene
environment risk assessment; NS, not significant.
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increased genetic risk of colon cancer. Motivations may
include to better mitigate high risks in their spouse, appro-
priately plan for possible future health problems and
needs, and to protect children and other loved ones from
similar health-related problems.
Several studies incorporating genetic susceptibility feed-
back testing have reported detailed information on uptake,
but only a handful have commented on predictors of
patient utilization of SNP-based biomarker testing for
disease risk. A study examining uptake of the GSTM1
biomarker via an online portal among patients recruited in
tandem through a smoking cessation trial found signifi-
cantly lower completion of testing (38%) relative to
reported interest in the available testing (63%) [11]. When
predictors of completion of testing were examined, uptake
was significantly associated with age (highest for 34 to 45
years; P = 0.04), awareness of genetic testing (P = 0.04),
greater motivation to quit smoking (P = 0.03), and with
internet access (P = 0.02). Updated data from Hensley-
Alford et al. [32] reported as part of the ongoing Multiplex
Initiative demonstrate AA race as a significant negative
predictor of uptake of a novel SNP-based risk assessment
panel. In particular, AAs were overall more indecisive
about genetic testing than whites and were less likely to
test (30% uptake among AAs vs 55% uptake among whites,
P < 0.0001). AAs from lower education neighborhoods
were least likely to complete the Multiplex testing. The
Multiplex group has previously reported [6] several demo-
graphic characteristics associated with completion of the
baseline survey (n = 1,959; 37% college graduate, 46%
male, 37% white). Bloss et al. recently reported an associa-
tion of race to completion of a direct-to-consumer SNP-
based genomic disease risk profile, with non-Whites being
less likely to complete testing and follow-up [33].
Individuals have been shown to express moderate to
high interest in genetic testing despite low knowledge
and understanding, but studies of testing uptake demon-
strate markedly lower rates of testing completion among
the underserved [21,26,41]. In particular, lower rates of
genetic testing uptake have been identified among AAs
[21,26,27]. Putative societal and socioeconomic factors
related to uptake include cost, insurance barriers, and
access to medical services for testing and counseling.
Recent literature from White et al. [13] has suggested
that AA patients may find approaches to disease risk
that focus only on genetics less appealing. Persistent
cultural barriers also include racial/ethnically founded
differences in fatalism or fears of genetic discrimination
[21,27,28,42] even when education levels are high [43].
Finally, research from Armstrong et al. has highlighted
apparent greater concerns about honesty in the US
healthcare system among AAs [34].
The average risk public lacks knowledge of genetics
and genetic testing [17-20]. The impact of low
knowledge about CRC, screening, or gene-environment
risks on uptake of an experimental gene-environment
genetic susceptibility test may be mediated by under-
standing (of testing terms or mechanisms), or perceived
relevance of testing. Whether parallels of testing experi-
ence in the GERA study can be drawn from the predic-
tive genetic testing literature is uncertain. When
predictive genetic testing has been studied, greater
objective knowledge has generally predicted testing
uptake among individuals at increased objective and
perceived risk, while more knowledgeable persons at
lower risk show less interest in testing [44], presumably
because they are more aware of their lower risk status
[24,44]. Underserved and minority populations have
been found to have notably lower objective knowledge
of genetic testing [17,18,21-25,42]. It is possible that in
the setting of relatively low knowledge about genetics or
experience with an experimental genetic test like GERA,
perceived risk of cancer may be less strongly associated
with interest in predictive genetic testing [23,45,46].
The strengths of the current study include the size of
the study sample, the large number of AA participants
in the study, and the non-hypothetical nature of the
genetic susceptibility testing offered to this diverse
cohort. The unique nature of the GERA testing, incor-
porating both genetic markers of risk and a dietary mar-
ker, also permits the exploration of how the public may
accept purely genetic susceptibility tests versus those
that offer exposure-related determinants of disease.
Among the limitations to this analysis is the inability to
further understand how individuals who opted to not
complete testing made this decision. Although unlikely, it
is also conceivable that a small number of individuals who
did not complete testing will still attempt to complete test-
ing. The small number of non-white non-AA participants
has made analyses of testing uptake for other underserved
or racial/ethnic groups impossible. Income data were also
not collected, limiting our ability to incorporate this rele-
vant factor into our multivariable logistic models. Finally,
because GERA testing is not standard of care, and was
offered in the context of a clinical trial, it remains uncer-
tain whether our study findings would predict the behavior
of patients faced with a recommended or standard genetic
susceptibility test in a real-world setting.
Conclusions
Multiple factors influence uptake of a moderate risk
gene-environment CRC susceptibility test among AA
and white patients participating in a clinical trial setting,
including objective risk status of the study population,
objective knowledge, race, and marital status. In particu-
lar, establishing relevance of a gene-environment test for
disease risk may be challenging in an objectively low-
risk, minority rich population with limited knowledge of
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the novel intervention test. Recruiting and supporting
clinical study participation and completion in a genetic
susceptibility study among average risk AAs will also
continue to be a challenge. Future studies incorporating
genetic susceptibility biomarkers may consider expanded
efforts to tailor pre-testing education to particularly dif-
ficult to reach groups like AA men [47] and to better
engage AA clinical trial participants to improve study
completion and follow-up. Public campaigns to improve
knowledge of CRC screening, risk factors, and genetics
could enable patients to make more informed genetic
testing choices [44,46]. Knowledgeable adults faced with
multiple health risks and financial concerns may con-
clude that a particular test, particularly one that conveys
only a modest increase in risk, is not sufficiently impor-
tant to warrant its uptake/completion.
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